Long-term survival after fludarabine, cyclophosphamide, and rituximab treatment in previously untreated chronic lymphocytic leukemia patients

Long-term survival after fludarabine, cyclophosphamide, and rituximab treatment in previously untreated chronic lymphocytic leukemia patients

BACKGROUND: Chronic lymphocytic leukemia (CLL) is characterized by a lower incidence rate in Iraq and Kurdistan as compared to Western countries. However, a good prognosis of CLL is dependable on diagnosis, risk stratification, and a better choice of an appropriate treatment regimen. AIM OF THE STUD...

Full description

Bibliographic Details
Main Authors: Shokhan Mohammad Mustafa, Ahmed Khudair Yassin, Nawsherwan S Mohammed, Rawand P Shamoon, Marwa N Karam, Shlan S Mohammad, Lara Lateef Abdulrahman, Zhalla O Ahmed, Bryar Sabah Rashid, Tavan I Mahmood, Rozhhat A Yousif, Kawa M Hasan, Zeki A Mohamed, Hisham A Getta, Sana D Jalal, Dana A Abdullah, Basil K Abdulla, Ghanim S Numan, Ranan Karadagh
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2021-01-01
Series:Iraqi Journal of Hematology
Subjects:
and rituximab
chronic lymphocytic leukemia
complete response
cyclophosphamide
fludarabine
survival
Online Access:http://www.ijhonline.org/article.asp?issn=2072-8069;year=2021;volume=10;issue=2;spage=139;epage=145;aulast=Mustafa

Internet

http://www.ijhonline.org/article.asp?issn=2072-8069;year=2021;volume=10;issue=2;spage=139;epage=145;aulast=Mustafa

Similar Items